menu search

Biomarin: growth drivers remain intact

During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline include...

October 19, 2023, 11:04 pm

Chmp endorses biomarin's (bmrn) voxzogo for use in infants

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia...

September 18, 2023, 3:03 pm

Bridgebio pharma announces positive feedback from the u.s. fda and eu ema on the regulatory path for a pivotal phase 3 trial of infigratinib in children with achondroplasia

– BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the Europe...

September 6, 2023, 11:30 am

Biomarin: fda approval of roctavian and massive voxzogo sales increase

BioMarin Pharmaceutical Inc. received FDA approval for ROCTAVIAN for adults with severe Hemophilia A. Net product revenues of VOXZOGO grew by 346% yea...

June 30, 2023, 6:08 pm

Bridgebio pharma shares gain on trial results for dwarfism drug

Shares of BridgeBio Pharma Inc. BBIO, -3.29% gained 5.5% premarket on Tuesday after the company announced that its investigational treatment for child...

June 20, 2023, 8:48 am

Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

June 8, 2023, 7:30 am

Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

June 8, 2023, 7:30 am

Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

June 8, 2023, 7:30 am

Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

June 8, 2023, 7:30 am

Bridgebio pharma to present updated six month results from its phase 2 cohort 5 study of infigratinib in achondroplasia in a late breaker oral presentation at the endocrine society (endo) 2023 annual

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

June 8, 2023, 7:30 am

Bridgebio pharma (bbio) surges 77% ytd: here's why

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infig...

March 22, 2023, 2:29 pm

Bridgebio pharma shares soar 55% on positive achondroplasia trial results

BridgeBio Pharma Inc shares have soared more than 55% after the company announced positive data from a Phase 2 clinical trial for its investigational ...

March 6, 2023, 1:21 pm

Why bridgebio pharma stock is skyrocketing today

BridgeBio announced positive phase 2 results for infigratinib in treating children with achondroplasia....

March 6, 2023, 12:22 pm

Biomarin's (bmrn) voxzogo expanded label filing accepted by ema

The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with ...

January 4, 2023, 12:47 pm

Once-weekly transcon™ cnp achieved primary efficacy objective, with superiority at 100 µg/kg/week, in ascendis pharma’s phase 2 accomplish trial of children with achondroplasia aged 2 to 10 years

– Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and conveni...

November 13, 2022, 11:15 pm


Search within

Pages Search Results: